{
    "id": "bae27c7b-f88a-4cbd-ba93-102203e24d60",
    "indications": "diclofenac sodium misoprostol delayed-release tablets indicated treatment signs symptoms osteoarthritis rheumatoid arthritis adult patients high risk developing nsaid-induced gastric duodenal ulcers complications . list factors may increase risk nsaid-induced gastric duodenal ulcers complications [ ( 5.3 ) ] .",
    "contraindications": "• lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) • osteoarthritis : recommended maximal gi protection one tablet ( containing 50 mg diclofenac 200 mcg misoprostol ) three times daily . diclofenac higher 150 mg/day recommended . ( 2.2 ) • rheumatoid arthritis : recommended maximal gi protection one tablet ( containing 50 mg diclofenac 200 mcg misoprostol ) three four times daily . diclofenac higher 200 mg/day recommended . ( 2.3 ) • modifications due intolerance , full prescribing information . ( 2.2 , 2.3 )",
    "warningsAndPrecautions": "diclofenac sodium misoprostol delayed-release tablets , usp supplied : 50 mg diclofenac sodium 200 mcg misoprostol round , biconvex , white off-white tablet imprinted “ ysp 167 ” . 75 mg diclofenac sodium 200 mcg misoprostol round , biconvex , white off-white tablet imprinted “ ysp 168 ” . strengths supplied : strength ndc number size 50 mg diclofenac sodiumand200 mcg misoprostol 75834-264-60 bottle 60 75834-264-90 bottle 90 75 mg diclofenac sodium 200 mcg misoprostol 75834-265-60 bottle 60 store dry area 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature ] .",
    "adverseReactions": "diclofenac sodium misoprostol delayed-release tablets contraindicated following patients : pregnancy . misoprostol , component diclofenac sodium misoprostol delayed-release tablets , pregnancy result maternal fetal harm , including uterine rupture , abortion , premature birth , birth defects [ ( 5.1 ) ( 8.1 ) ] setting coronary artery bypass graft ( cabg ) surgery [ ( 5.2 ) ] active gastrointestinal bleeding [ ( 5.3 ) ] history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.8 , 5.9 ) ] known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac sodium misoprostol , prostaglandins , components product [ ( 5.8 , 5.10 ) ]",
    "ingredients": [
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        },
        {
            "name": "MISOPROSTOL",
            "code": "0E43V0BB57"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        }
    ],
    "organization": "Nivagen Pharmaceuticals, Inc.",
    "name": "Diclofenac Sodium Misoprostol",
    "effectiveTime": "20250416",
    "indications_original": "Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications [see Warnings and Precautions (5.3)].",
    "contraindications_original": "• Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.1 ) • Osteoarthritis: The recommended dosage for maximal GI protection is one tablet (containing 50 mg of diclofenac and 200 mcg of misoprostol) three times daily. A dosage of diclofenac higher than 150 mg/day is not recommended. ( 2.2 ) • Rheumatoid Arthritis: The recommended dosage for maximal GI protection is one tablet (containing 50 mg of diclofenac and 200 mcg of misoprostol) three or four times daily. A dosage of diclofenac higher than 200 mg/day is not recommended. ( 2.3 ) • For dosage modifications due to intolerance, see the full Prescribing Information. ( 2.2 , 2.3 )",
    "warningsAndPrecautions_original": "Diclofenac sodium and misoprostol delayed-release tablets, USP are supplied as: \n                  \n                     50 mg diclofenac sodium and 200 mcg misoprostol as round, biconvex, white to off-white tablet imprinted with “YSP 167”.\n                     75 mg diclofenac sodium and 200 mcg misoprostol as round, biconvex, white to off-white tablet imprinted with “YSP 168”.\n                  \n                  The dosage strengths are supplied in:\n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Strength\n                              \n                           \n                           \n                              NDC Number\n                              \n                           \n                           \n                              Size\n                              \n                           \n                        \n                        \n                           50 mg diclofenac sodiumand200 mcg misoprostol\n                           \n                           75834-264-60\n                           \n                           bottle of 60\n                           \n                        \n                        \n                           75834-264-90\n                           \n                           bottle of 90\n                           \n                        \n                        \n                           75 mg diclofenac sodium and 200 mcg misoprostol\n                           \n                           75834-265-60\n                           \n                           bottle of 60\n                           \n                        \n                     \n                  \n                  \n                  Store in a dry area at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients:\n                  \n                     Pregnancy. Use of misoprostol, a component of diclofenac sodium and misoprostol delayed-release tablets, during pregnancy can result in maternal and fetal harm, including uterine rupture, abortion, premature birth, or birth defects  [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]\n                     \n                     In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.2)]\n                     \n                     Active gastrointestinal bleeding [see Warnings and Precautions (5.3)]\n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8, 5.9)]\n                     \n                      Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see Warnings and Precautions (5.8, 5.10)]"
}